MET and familial pancreatic carcinoma: Consistent with our results, a ‘triple therapy’ (inhibition of both HGF and MET combined with gemcitabine) has been recently shown to achieve stronger inhibition of both primary tumor growth and metastatic dissemination compared to the single treatments or dual combinations in a mouse model of pancreatic cancer [110].